MedPath

Hanlim Pharm Co., Ltd.

Hanlim Pharm Co., Ltd. logo
🇰🇷South Korea
Ownership
Private
Established
1989-03-14
Employees
251
Market Cap
-
Website
http://hanlim.com

Clinical Trials

49

Active:2
Completed:33

Trial Phases

4 Phases

Phase 1:20
Phase 2:6
Phase 3:12
+1 more phases

Drug Approvals

12

PHILIPPINES:12

Drug Approvals

Toprasenz

Approval Date
Jul 14, 2025
PHILIPPINES

Predsenz

Approval Date
Jul 14, 2025
PHILIPPINES

Moxiforce

Approval Date
Jul 14, 2025
PHILIPPINES

Tracsiban

Approval Date
Jul 14, 2025
PHILIPPINES

Prasenz

Approval Date
Jul 14, 2025
PHILIPPINES

Moxidin

Approval Date
Jul 14, 2025
PHILIPPINES

Predyl 500

Approval Date
Jul 14, 2025
PHILIPPINES

Protoza 40

Approval Date
Jul 14, 2025
PHILIPPINES

Axepron

Approval Date
Jul 14, 2025
PHILIPPINES

Acceluron

Approval Date
Jul 14, 2025
PHILIPPINES
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials

Phase 1
20 (47.6%)
Phase 3
12 (28.6%)
Phase 2
6 (14.3%)
Phase 4
4 (9.5%)

Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

Phase 1
Completed
Conditions
Gastric Ulcer
Interventions
First Posted Date
2024-10-15
Last Posted Date
2024-10-16
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06642987
Locations
🇰🇷

Seok Gyeong Medical Foundation Central Hospital, Siheung-si, Korea, Republic of

Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects

Phase 1
Completed
Conditions
Primary Hypercholesterolemia
Combined Hyperlipidemia
Interventions
Drug: Crecheck Tablet 2.5 mg
First Posted Date
2024-06-26
Last Posted Date
2024-06-27
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
36
Registration Number
NCT06475872
Locations
🇰🇷

Seok Gyeong Medical Foundation Central Hospital, Gyeonggi-do, Korea, Republic of

Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease

Phase 2
Recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Other: Placebo
Drug: Bronpass Tab.
First Posted Date
2024-05-30
Last Posted Date
2024-05-30
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
96
Registration Number
NCT06434792
Locations
🇰🇷

Konkuk University School of Medicine, Seoul, Korea, Republic of

Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection

Recruiting
Conditions
Reversal of Neuromuscular Blockade
First Posted Date
2024-02-07
Last Posted Date
2024-02-07
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
1500
Registration Number
NCT06246331
Locations
🇰🇷

Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of

An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)

Recruiting
Conditions
Hypertension
First Posted Date
2024-01-22
Last Posted Date
2024-01-22
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
4000
Registration Number
NCT06214832
Locations
🇰🇷

Seoul song clinic, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.